Regeneron works to secure fianlimab
A just revealed phase 3 trial will apparently pit a fixed-dose combo head to head against Opdualag.
AbbVie sees a world according to GARP
On a wing and a prayer AbbVie takes livmoniplimab into phase 3.
Roche perseveres with FAP
A third discontinuation leaves one anti-FAP project in Roche’s clinical pipeline.
Novartis calls time on TIM-3 and HIF2α
The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.
